Incannex reports positive Phase 2 results for IHL-42X in obstructive sleep apnea; AHI reduced up to 83%

Incannex Healthcare Inc.

IHL-42X reduced AHI up to 83% (high-dose) and 79% (low-dose) from baseline; 41.2% of high-dose patients achieved >30% reduction.
Statistically significant improvements in PGI-C sleep related impairment, fatigue, ODI, and patient-reported outcomes (FOSQ-10, ESS, PROMIS).
No serious adverse events reported; treatment-emergent adverse effects infrequent, mostly mild/moderate.
Preparing End-of-Phase 2 meeting with FDA; advancing toward commercial readiness and Phase 3 development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.